5:15 PM
 | 
Sep 28, 2009
 |  BC Extra  |  Top Story

Crucell, J&J in influenza deal

Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) and Johnson & Johnson (NYSE:JNJ) partnered to discover, develop and commercialize mAbs and vaccines to treat and prevent influenza and other infectious and non-infectious diseases. J&J made an equity investment of EUR 301.8 million ($440.8 million) in Crucell though...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >